Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4872056
Max Phase: Preclinical
Molecular Formula: C118H163Cl2N39O22
Molecular Weight: 2550.76
Molecule Type: Unknown
Associated Items:
ID: ALA4872056
Max Phase: Preclinical
Molecular Formula: C118H163Cl2N39O22
Molecular Weight: 2550.76
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC[C@@H](C)[C@@H]1NC(=O)[C@H](Cc2cn(CCc3c(C)[nH]c4cc(Cl)cc(Cl)c34)nn2)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](C)NC(=O)c2cc3cc(c2)C(=O)NC[C@@H](C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc2ccc4ccccc4c2)NC(=O)[C@H](Cc2ccccc2)NC(=O)C(CCCCNC3=O)NC(=O)[C@H](CC(=O)O)NC1=O
Standard InChI: InChI=1S/C118H163Cl2N39O22/c1-7-61(4)94-113(181)154-89(57-92(161)162)111(179)145-76-29-16-17-38-133-97(165)69-50-70(52-71(51-69)99(167)141-63(6)96(164)148-83(45-60(2)3)106(174)150-84(47-64-23-10-8-11-24-64)107(175)147-80(33-21-42-137-117(129)130)104(172)153-88(56-91(121)160)110(178)152-87(112(180)156-94)55-73-59-159(158-157-73)44-37-74-62(5)140-82-54-72(119)53-75(120)93(74)82)98(166)139-58-90(95(122)163)155-105(173)81(34-22-43-138-118(131)132)144-101(169)78(31-19-40-135-115(125)126)142-100(168)77(30-18-39-134-114(123)124)143-102(170)79(32-20-41-136-116(127)128)146-108(176)86(49-66-35-36-67-27-14-15-28-68(67)46-66)151-109(177)85(149-103(76)171)48-65-25-12-9-13-26-65/h8-15,23-28,35-36,46,50-54,59-61,63,76-81,83-90,94,140H,7,16-22,29-34,37-45,47-49,55-58H2,1-6H3,(H2,121,160)(H2,122,163)(H,133,165)(H,139,166)(H,141,167)(H,142,168)(H,143,170)(H,144,169)(H,145,179)(H,146,176)(H,147,175)(H,148,164)(H,149,171)(H,150,174)(H,151,177)(H,152,178)(H,153,172)(H,154,181)(H,155,173)(H,156,180)(H,161,162)(H4,123,124,134)(H4,125,126,135)(H4,127,128,136)(H4,129,130,137)(H4,131,132,138)/t61-,63-,76?,77+,78+,79+,80+,81+,83-,84+,85+,86+,87+,88-,89+,90+,94+/m1/s1
Standard InChI Key: NFGKGHDHIHVEDO-ANCQKIQRSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 2550.76 | Molecular Weight (Monoisotopic): 2548.2212 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Buyanova M, Cai S, Cooper J, Rhodes C, Salim H, Sahni A, Upadhyaya P, Yang R, Sarkar A, Li N, Wang QE, Pei D.. (2021) Discovery of a Bicyclic Peptidyl Pan-Ras Inhibitor., 64 (17.0): [PMID:34415745] [10.1021/acs.jmedchem.1c01130] |
Source(1):